Technology Platforms

We continue to apply our PEGylation technology to a broad range of therapies, such as the PEGylated version of SN38, which has shown very encouraging results in preclinical studies.” — Hong Zhao Ph.D., Director, Organic and Medicinal Chemistry. Enzon is dedicated to developing innovative therapies through a variety of advanced technologies. Enzon’s proprietary PEGylation technology is a proven means of enabling or enhancing the performance of pharmaceuticals with delivery limitations, through the chemical attachment of polyethylene glycol or PEG via a linker. Advantages of PEGylation include increased efficacy, reduced toxicity, increased stability, and enhanced solubility. Click here to learn more about Enzon’s PEGylation technologies. Enzon has also developed Customized Linker Technology™, which utilizes linkers designed to release the native molecule at a controlled rate. Enzon is also developing eight innovative RNA antagonists based on the locked Nucleic Acid® (LNA) Technology. Click here to learn more about this technology.